Drug Trial Radar · NCT05778188
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
173
Planned (sponsor's estimate)
Start
Jul 27, 2023
Primary completion
Dec 2026
Study completion Dec 2028
Sponsor
- Lead sponsor
- ReAlta Life Sciences, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Premier Research
- First posted
- Mar 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 10 hours
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hypoxic-ischemic encephalopathy (HIE) affects approximately 4,000 to 12,000 persons annually in the United States. Mortality from HIE has been reported up to 60%, with at least 25% of survivors left with significant neurocognitive disability. Despite this vital unmet medical need, no pharmacological adjunct or alternative therapy has proven beneficial in improving outcomes in neonatal HIE. RLS-0071 is a novel peptide being developed for the treatment of neonatal HIE. This study is designed to evaluate the efficacy, safety, and tolerability of RLS-0071 in the treatment of newborns with moderate or severe HIE.
Conditions
- Hypoxic-Ischemic Encephalopathy
Interventions
RLS-0071Drug
RLS-0071 (unit strength 10 mg/mL) will be administered by infusion for a dose level of 3 or 10 mg/kg. Planned infusion duration is 10 minutes for all dose levels.
PlaceboDrug
Placebo control (commercial sterile saline) will be administered by infusion at a volume matched to RLS-0071 (3 or 10 mg/kg). Planned infusion duration is 10 minutes for all matched dose levels.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Extent of acute brain injury at Day 4 (+3), assessed through magnetic resonance imaging (MRI), using a standardized scoring systemTime frame: Day 4 (up to Day 7)
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Study Site 016
Little Rock, Arkansas · Recruiting
Study Site 013
Orange, California · Recruiting
Study Site 020
San Diego, California · Recruiting
Study Site 019
San Diego, California · Recruiting
Study Site 027
Aurora, Colorado · Recruiting
Study Site 001
Gainesville, Florida · Recruiting
Study Site 018
Miami, Florida · Recruiting
Study Site 010
Orlando, Florida · Recruiting
Study Site 014
Indianapolis, Indiana · Recruiting
Study Site 012
Lexington, Kentucky · Withdrawn
Study Site 025
Louisville, Kentucky · Recruiting
Study Site 029
Boston, Massachusetts · Recruiting
Study Site 002
Boston, Massachusetts · Recruiting
Study Site 006
St Louis, Missouri · Recruiting
Study Site 024
Manhasset, New York · Recruiting
Study Site 023
New Hyde Park, New York · Recruiting
Study Site 028
New York, New York · Recruiting
Study Site 003
Durham, North Carolina · Recruiting
Study Site 021
Cleveland, Ohio · Recruiting
Study Site 022
Fort Worth, Texas · Recruiting
Study Site 030
Houston, Texas · Recruiting
Study Site 005
Morgantown, West Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.